Singapore Institute of Advanced Medicine Holdings Ltd. (SGX:9G2)

SGXC:9G2 Cash Flow Statement

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-28.87	-37.45	-18.07	-12.43	-9.35
Depreciation & Amortization	12.46	12.46	5.76	5.25	5.13
Other Amortization	0.01	0.01	0.01	0.01	0
Loss (Gain) From Sale of Assets	-	-0.01	-0.62	-0.84	-
Asset Writedown & Restructuring Costs	0	-	-0.5	-1.65	-
Stock-Based Compensation	-0.08	-0.07	-0.16	0.42	0.46
Other Operating Activities	7.84	16.42	5.24	0.97	0.92
Change in Accounts Receivable	0.03	0.68	0.65	-0.45	0.79
Change in Inventory	-0.01	0	-0.01	0.01	0.01
Change in Accounts Payable	-5.46	-5.03	4.4	2.2	0.4
Change in Other Net Operating Assets	-0.09	0.05	0.06	0.71	-0.78
Operating Cash Flow	-14.17	-12.93	-3.24	-5.81	-2.43
Capital Expenditures	-0.39	-0.53	-14.44	-4.09	-5.45
Sale of Property, Plant & Equipment	-	0.01	-	3.8	-
Sale (Purchase) of Intangibles	-	-	-	-0.02	-0.02
Other Investing Activities	0.26	0.27	0.26	0.28	0.22
Investing Cash Flow	-0.13	-0.26	-1.45	3.72	-5.25
Short-Term Debt Issued	-	-	3.1	-	-
Long-Term Debt Issued	-	7	21.82	24.74	17.24
Total Debt Issued	11.92	7	24.92	24.74	17.24
Long-Term Debt Repaid	-	-25.73	-21.27	-14.2	-4.9
Net Debt Issued (Repaid)	-9.6	-18.73	3.64	10.54	12.34
Issuance of Common Stock	26.22	26.22	-	-	-
Other Financing Activities	-1.96	-2.2	-3.74	-2.7	-3.51
Financing Cash Flow	14.67	5.3	-0.1	7.84	8.83
Net Cash Flow	0.37	-7.89	-4.79	5.75	1.16
Free Cash Flow	-14.56	-13.46	-17.68	-9.89	-7.87
Free Cash Flow Margin	-90.25%	-80.88%	-108.89%	-71.66%	-60.94%
Free Cash Flow Per Share	-0.01	-0.02	-0.03	-0.01	-0.01
Cash Interest Paid	1.96	2.7	3.67	2.91	3.48
Levered Free Cash Flow	-	-27.05	-19.34	3.48	-
Unlevered Free Cash Flow	-	-20.04	-17.93	4.12	-
Change in Net Working Capital	-	18.95	0.46	-10.89	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.